W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

PKCα

PKCα

Overview

PKCα, or protein kinase C alpha, is a member of the protein kinase C family and is encoded by PRKCA. It is a calcium-responsive signaling kinase that participates in phosphorylation-dependent regulation of diverse cellular processes. In biomedical research, PKCα is commonly discussed as a signaling node linking extracellular stimuli to changes in cell survival, cytoskeletal organization, membrane dynamics, and gene regulation.

Clinically and experimentally, PKCα has attracted attention in contexts where aberrant kinase signaling contributes to disease. Recent studies have highlighted its involvement in heart failure, tumor immune resistance, and stress responses in blood cells and neurons. Its activity can be modulated by upstream signals involving calcium, and it has been studied alongside other kinase pathways such as glycogen synthase kinase 3β and Ca2+/calmodulin-dependent protein kinase II, reflecting its role in broader phosphorylation networks.

Focus of Latest Publications

Recent publications have examined PKCα as both a mechanistic signaling mediator and a potential therapeutic target across distinct disease settings.

In cardiovascular research, a 2026 study in Circulation Research reported that PKCα (protein kinase C alpha), encoded by PRKCA, plays a central role in heart failure pathogenesis. The study title indicates that ablation of PKCα phosphorylation by CRISPR-Cas9 base editing rescues heart failure, suggesting that phosphorylation of PKCα is functionally important in disease progression and that targeted editing of this modification can reverse pathological effects. This work places PKCα at the center of a disease-relevant signaling mechanism rather than merely as a downstream marker.

In oncology, a 2026 PNAS study identified substrate-based protein kinase C (PKC) activity as a prognostic biomarker in non-small cell lung cancer and a therapeutic target in anti-PD-1-refractory tumors. The publication context specifically links PKC signaling to resistance to anti-PD-1/PD-L1 therapy and to rechallenge strategies involving anti-CTLA-4. Although the excerpt refers to PKC activity broadly rather than PKCα alone, PKCα is a major PKC isoform and is relevant to the signaling framework under investigation. The study also mentions XIAP-coordinated PKC signaling, indicating that PKC-dependent pathways may be integrated with apoptosis and immune-response regulation in refractory tumors.

A separate 2026 study in Chemico-Biological Interactions examined the effects of heating tobacco product extract on red blood cells and reported that the extract promoted PKCα membrane translocation. The same context states that PKC inhibition with staurosporine completely suppressed eryptosis and cytoskeletal phosphorylation, supporting a causal role for PKCα-linked signaling in tobacco aerosol-induced erythrocyte injury. This work connects PKCα to membrane-associated activation events and downstream structural phosphorylation changes.

Another 2026 study in PLoS Pathogens used a chemo-omic pipeline to identify pathways and inhibitory compounds affecting prion-related synaptotoxicity. The compounds converged on three protein kinase targets: Ca2+/calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC), and glycogen synthase kinase 3β (GSK3β). While PKCα is not singled out in the excerpt, the study reinforces PKC-family involvement in neuronal toxicity pathways and places PKC signaling in the same mechanistic space as calcium-dependent and glycogen synthase kinase pathways.

Taken together, these studies portray PKCα as a signaling kinase with disease relevance in heart failure, immune-resistant cancer, and toxic stress responses. The recurring themes are phosphorylation-dependent regulation, membrane translocation, and pathway convergence with calcium-linked and stress-response kinases.

Key Publications

  • Jun Chemo-omic pipeline enables discovery of prion synaptotoxic pathways and inhibitory drugs. (PLoS pathogens, 2026, PMID 42313800): "These compounds converged on three protein kinase targets: Ca2+/calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC), and glycogen synthase kinase 3β (GSK3β)."
  • Jun Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42234523): "Here, we identify substrate-based protein kinase C (PKC) activity as a prognostic biomarker in non-small cell lung cancer and a therapeutic target in anti-PD-1-refractory tumors."
  • May Tobacco heating product aerosol triggers PKC-dependent eryptosis: biochemical insights. (Chemico-biological interactions, 2026, PMID 41796629): "Moreover, HTPE promoted PKCα membrane translocation, and PKC inhibition with staurosporine completely suppressed eryptosis and cytoskeletal phosphorylation."
  • Apr Ablation of PKCα Phosphorylation by CRISPR-Cas9 Base Editing Rescues Heart Failure. (Circulation research, 2026, PMID 41717698): "PKCα (protein kinase C alpha), encoded by PRKCA, plays a central role in heart failure pathogenesis."
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.